CAMBRIDGE, Mass. April 9, 2020 – Tango Therapeutics, a biotechnology company focused on discovering and delivering the next generation of targeted cancer therapies, today announced the closing of an oversubscribed Series B financing of $60 million led by Boxer Capital of the Tavistock Group. Cormorant Asset Management and Casdin Capital are additional new investors in the round.
“We are very fortunate to have the support of this strong syndicate of cross-over investors as we bring our first targeted therapies based on the genetic concept of synthetic lethality to well-defined patient populations,” said Barbara Weber, MD, President and Chief Executive Officer of Tango. “This financing will support our lead program into IND-enabling studies early next year as well multiple other ongoing target and drug discovery efforts.”
Additionally, Tango announced leadership appointments of Daniella Beckman, Chief Financial Officer, John C. Ross, Vice President of Human Resources and Samy Tadros, Vice President of Business Development.
Read more here.